Search

Your search keyword '"Tomsic, Matija"' showing total 149 results
Start Over Author "Tomsic, Matija" Search Limiters Full Text
149 results on '"Tomsic, Matija"'

1. Molecular maps of synovial cells in inflammatory arthritis using an optimized synovial tissue dissociation protocol

Author

Edalat, Sam G., Gerber, Reto, Houtman, Miranda, Lückgen, Janine, Teixeira, Rui Lourenço, Palacios Cisneros, Maria del Pilar, Pfanner, Tamara, Kuret, Tadeja, Ižanc, Nadja, Micheroli, Raphael, Polido-Pereira, Joaquim, Saraiva, Fernando, Lingam, Swathi, Burki, Kristina, Burja, Blaž, Pauli, Chantal, Rotar, Žiga, Tomšič, Matija, Čučnik, Saša, Fonseca, João Eurico, Distler, Oliver, Calado, Ângelo, Romão, Vasco C., Ospelt, Caroline, Sodin-Semrl, Snežna, Robinson, Mark D., and Frank Bertoncelj, Mojca

Published
2024
Full Text
View/download PDF

2. Solvation of Nonionic Poly(Ethylene Oxide) Surfactant Brij 35 in Organic and Aqueous-Organic Solvents

Author

Cerar, Jure, Jamnik, Andrej, Szilágyi, István, and Tomšič, Matija

Subjects
Condensed Matter - Soft Condensed Matter
Abstract

Hypothesis: By combining the experimental small- and wide-angle x-ray scattering (SWAXS) method with molecular dynamics simulations and the theoretical 'complemented-system approach' it is possible to obtain detailed information about the intra- and inter-molecular structure and dynamics of the solvation and hydration of the surfactant in organic and mixed solvents, e.g., of the nonionic surfactant Brij 35 (C12E23) in alcohols and aqueous alcohol-rich ternary systems. This first application of the complemented-system approach to the surfactant system will promote the use of this powerful methodology that is based on experimental and calculated SWAXS data in studies of colloidal systems. By applying high-performance computing systems, such an approach is readily available for studies in the colloidal domain. Experiments: SWAXS experiments and MD simulations were performed for binary Brij 35/alcohol and ternary Brij 35/water/alcohol systems with ethanol, n-butanol and n-hexanol as the organic solvent component at 25 {\deg}C. Findings: We confirmed the presence of solvated Brij 35 monomers in the studied organic media, revealed their preferential hydration and discussed their structural and dynamic features at the intra- and inter-molecular levels. Anisotropic effective surfactant molecular conformations were found. The influence of the hydrophobicity of the organic solvent on the hydration phenomena of surfactant molecules was explained., Comment: 31 pages, 6 figures, 1 table

Published
2021
Full Text
View/download PDF

3. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Author

Michelsen, Brigitte, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian, Möller, Burkhard, Ørnbjerg, Lykke Midtbøll, Zavada, Jakub, Glintborg, Bente, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Ziga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovsky, Jiri, Loft, Anne Gitte, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José, Mogosan, Corina, Tomsic, Matija, Díaz-González, Federico, Di Giuseppe, Daniela, and Hetland, Merete Lund

Published
2023
Full Text
View/download PDF

4. Structural, Rheological and Dynamic Aspects of Hydrogen-Bonding Molecular Liquids: Aqueous Solutions of Hydrotropic tert-Butyl Alcohol

Author

Cerar, Jure, Jamnik, Andrej, Pethes, Ildikó, Temleitner, László, Pusztai, László, and Tomsic, Matija

Subjects
Condensed Matter - Soft Condensed Matter
Abstract

Hypothesis: The structural details, viscosity trends and dynamic phenomena in t-butanol/water solutions are closely related on the molecular scales across the entire composition range. Utilizing the experimental small- and wide-angle x-ray scattering (SWAXS) method, molecular dynamics (MD) simulations and the complemented-system approach method developed in our group it is possible to comprehensively describe the structure-viscosity-dynamics relationship in such structurally versatile hydrogen-bonded molecular liquids, as well as in similar, self-assembling systems with pronounced molecular and supramolecular structures at the intra-, inter-, and supra-molecular scales. Experiments: The SWAXS and x-ray diffraction experiments and MD simulations were performed for aqueous t-butanol solutions at 25 {\deg}C. Literature viscosity and self-diffusion data were also used. Findings: The interpretive power of the proposed scheme was demonstrated by the extensive and diverse results obtained for aqueous t-butanol solutions across the whole concentration range. Four composition ranges with qualitatively different structures and viscosity trends were revealed. The experimental and calculated zero-shear viscosities and molecular self-diffusion coefficients were successfully related to the corresponding structural details. The hydrogen bonds, that were, along with hydrophobic effects, recognized as the most important driving force for the formation of t-butanol aggregates, show intriguing lifetime trends and thermodynamic properties of their formation., Comment: Main manuscript file AND Supplemental Information, united in one file

Published
2019
Full Text
View/download PDF

5. Unexpected composition dependence of the first sharp diffraction peak in an alcohol-aldehyde liquid mixture: n-pentanol and pentanal

Author

Pethes, Ildikó, Temleitner, László, Tomšič, Matija, Jamnik, Andrej, and Pusztai, László

Subjects
Physics - Chemical Physics, Condensed Matter - Soft Condensed Matter
Abstract

The total scattering structure factors of pure liquid n-pentanol, pentanal, and 5 of their mixtures, as determined by high energy synchrotron X-ray diffraction experiments, are presented. For the interpretation of measured data, molecular dynamics computer simulations are performed, utilizing 'all-atom' type force fields. The diffraction signals in general resemble each other over most of the monitored Q range above 1 ${\AA}^{-1}$, but the absolute values of the intensities of the small-angle scattering maximum ('pre-peak', 'first sharp diffraction peak'), around 0.6 ${\AA}^{-1}$, change in an unexpected fashion, non-linearly with the composition. MD simulations are not able to reproduce this low-Q behavior; on the other hand, they do reproduce the experimental diffraction data above 1 ${\AA}^{-1}$ rather accurately. Partial radial distribution functions are calculated based on the atomic coordinates in the simulated configurations. Inspection of the various O-O and O-H partial radial distribution functions clearly shows that both the alcoholic and the aldehydic oxygens form hydrogen bonds with the hydrogen atoms of the alcoholic OH-group., Comment: This is the pre-peer reviewed version of the article, which has been published in final form at Physica Status Solidi B

Published
2018
Full Text
View/download PDF

6. X-ray diffraction and computer simulation studies of the structure of liquid aliphatic aldehydes: from propanal to nonanal

Author

Pethes, Ildikó, Temleitner, László, Tomšič, Matija, Jamnik, Andrej, and Pusztai, László

Subjects
Physics - Chemical Physics, Condensed Matter - Soft Condensed Matter
Abstract

Synchrotron X-ray diffraction experiments and molecular dynamics simulations have been performed on simple aliphatic aldehydes, from propanal to nonanal. The performance of the OPLS all-atom interaction potential model for aldehydes has been assessed via direct comparison of simulated and experimental total scattering structure factors. In general, MD results reproduce the experimental data at least semi-quantitatively. However, a slight mismatch can be observed between the two datasets in terms of the position of the main diffraction maxima. Partial radial distribution functions have also been calculated from the simulation results. Clear differences could be detected between the various O-H partial radial distribution functions, depending on whether the H atom is attached to the carbon atom that is doubly bonded to the oxygen atom of the aldehyde group or not., Comment: This is the pre-peer reviewed version of the article, which has been published in final form at Physica Status Solidi B

Published
2018
Full Text
View/download PDF

8. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Author

Michelsen, Brigitte, Georgiadis, Stylianos, Di Giuseppe, Daniela, Loft, Anne G., Nissen, Michael J., Iannone, Florenzo, Pombo‐Suarez, Manuel, Mann, Herman, Rotar, Ziga, Eklund, Kari K., Kvien, Tore K., Santos, Maria J., Gudbjornsson, Bjorn, Codreanu, Catalin, Yilmaz, Sema, Wallman, Johan K., Brahe, Cecilie H., Möller, Burkhard, Favalli, Ennio G., Sánchez‐Piedra, Carlos, Nekvindova, Lucie, Tomsic, Matija, Trokovic, Nina, Kristianslund, Eirik K., Santos, Helena, Löve, Thorvardur J., Ionescu, Ruxandra, Pehlivan, Yavuz, Jones, Gareth T., van der Horst‐Bruinsma, Irene, Ørnbjerg, Lykke M., Østergaard, Mikkel, and Hetland, Merete L.

Published
2022
Full Text
View/download PDF

11. The Complemented System Approach: A Novel Method for Calculating the X-ray Scattering from Computer Simulations

Author

Lajovic, Andrej, Tomšič, Matija, and Jamnik, Andrej

Subjects
Condensed Matter - Statistical Mechanics, Physics - Chemical Physics
Abstract

In this paper, we review the main problem concerning the calculation of X-ray scattering of simulated model systems, namely their finite size. A novel method based on the Rayleigh-Debye-Gans approximation was derived, which allows sidestepping this issue by complementing the missing surroundings of each particle with an average image of the system. The method was designed to operate directly on particle configurations without an intermediate step (e.g., calculation of pair distribution functions): in this way, all information contained in the configurations was preserved. A comparison of the results against those of other known methods showed that the new method combined several favourable properties: an arbitrary q-scale, scattering curves free of truncation artifacts and good behaviour down to the theoretical lower limit of the q-scale. A test of computational efficiency was also performed to establish a relative scale between the speeds of all known methods: the reciprocal lattice approach, the brute force method, the Fourier transform approach and the newly presented complemented system approach., Comment: 6 pages, 5 figures. Copyright 2010 American Institute of Physics. This article may be downloaded for personal use only. Any other use requires prior permission of the author and the American Institute of Physics. The following article appeared in The Journal of Chemical Physics and may be found at http://link.aip.org/link/?jcp/133/174123

Published
2010
Full Text
View/download PDF

16. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

Author

Nissen, Michael, Delcoigne, Bénédicte, Di Giuseppe, Daniela, Jacobsson, Lennart, Hetland, Merete Lund, Ciurea, Adrian, Nekvindova, Lucie, Iannone, Florenzo, Akkoc, Nurullah, Sokka-Isler, Tuulikki, Fagerli, Karen Minde, Santos, Maria Jose, Codreanu, Catalin, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, van der Horst-Bruinsma, Irene, Loft, Anne Gitte, Möller, Burkhard, Mann, Herman, Conti, Fabrizio, Yildirim Cetin, Gozde, Relas, Heikki, Michelsen, Brigitte, Avila Ribeiro, Pedro, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Tomsic, Matija, Geirsson, Árni Jón, Askling, Johan, Glintborg, Bente, Lindström, Ulf, Nissen, Michael, Delcoigne, Bénédicte, Di Giuseppe, Daniela, Jacobsson, Lennart, Hetland, Merete Lund, Ciurea, Adrian, Nekvindova, Lucie, Iannone, Florenzo, Akkoc, Nurullah, Sokka-Isler, Tuulikki, Fagerli, Karen Minde, Santos, Maria Jose, Codreanu, Catalin, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, van der Horst-Bruinsma, Irene, Loft, Anne Gitte, Möller, Burkhard, Mann, Herman, Conti, Fabrizio, Yildirim Cetin, Gozde, Relas, Heikki, Michelsen, Brigitte, Avila Ribeiro, Pedro, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Tomsic, Matija, Geirsson, Árni Jón, Askling, Johan, Glintborg, Bente, and Lindström, Ulf

Abstract

OBJECTIVES: Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis. METHODS: Data was collected from 13 European registries. One-year outcomes included TNFi retention and hazard ratios (HR) for discontinuation with 95% CIs. Logistic regression was performed with adjusted odds ratios (OR) of achieving remission (Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP < 1.3 and/or BASDAI < 2) and stratified by treatment. Inter-registry heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Peripheral arthritis was defined as ≥1 swollen joint at baseline (=TNFi start). RESULTS: Amongst 24 171 axSpA patients, 32% received csDMARD co-therapy (range across countries: 13.5% to 71.2%). The co-therapy group had more baseline peripheral arthritis and higher CRP than the monotherapy group. One-year TNFi-retention rates (95% CI): 79% (78, 79%) for TNFi monotherapy vs 82% (81, 83%) with co-therapy (P < 0.001). Remission was obtained in 20% on monotherapy and 22% on co-therapy (P < 0.001); adjusted OR of 1.16 (1.07, 1.25). Remission rates at 12 months were similar in patients with/without peripheral arthritis. CONCLUSION: This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy.

Published
2022

17. European bio-naïve spondyloarthritis patients initiating TNF inhibitor:time trends in baseline characteristics, treatment retention and response

Author

Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Rasmussen, Simon Horskjær, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fatos, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J., Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Van der Horst-Bruinsma, Irene, Di Giuseppe, Daniela, Glintborg, Bente, Gremese, Elisa, Pavelka, Karel, Kristianslund, Eirik Klami, Ciurea, Adrian, Akkoc, Nurullah, Barcelos, Anabela, Sánchez-Piedra, Carlos, Peltomaa, Ritva, Jones, Gareth T., Rotar, Ziga, Ionescu, Ruxandra, Grondal, Gerdur, Van de Sande, Marleen G.H., Laas, Karin, Østergaard, Mikkel, Hetland, Merete L., Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Rasmussen, Simon Horskjær, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fatos, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J., Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Van der Horst-Bruinsma, Irene, Di Giuseppe, Daniela, Glintborg, Bente, Gremese, Elisa, Pavelka, Karel, Kristianslund, Eirik Klami, Ciurea, Adrian, Akkoc, Nurullah, Barcelos, Anabela, Sánchez-Piedra, Carlos, Peltomaa, Ritva, Jones, Gareth T., Rotar, Ziga, Ionescu, Ruxandra, Grondal, Gerdur, Van de Sande, Marleen G.H., Laas, Karin, Østergaard, Mikkel, and Hetland, Merete L.

Abstract

OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. METHODS: Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. RESULTS: In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. CONCLUSION: Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.

Published
2022

18. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

Author

Nissen, Michael, primary, Delcoigne, Bénédicte, additional, Di Giuseppe, Daniela, additional, Jacobsson, Lennart, additional, Hetland, Merete Lund, additional, Ciurea, Adrian, additional, Nekvindova, Lucie, additional, Iannone, Florenzo, additional, Akkoc, Nurullah, additional, Sokka-Isler, Tuulikki, additional, Fagerli, Karen Minde, additional, Santos, Maria Jose, additional, Codreanu, Catalin, additional, Pombo-Suarez, Manuel, additional, Rotar, Ziga, additional, Gudbjornsson, Bjorn, additional, van der Horst-Bruinsma, Irene, additional, Loft, Anne Gitte, additional, Möller, Burkhard, additional, Mann, Herman, additional, Conti, Fabrizio, additional, Yildirim Cetin, Gozde, additional, Relas, Heikki, additional, Michelsen, Brigitte, additional, Avila Ribeiro, Pedro, additional, Ionescu, Ruxandra, additional, Sanchez-Piedra, Carlos, additional, Tomsic, Matija, additional, Geirsson, Árni Jón, additional, Askling, Johan, additional, Glintborg, Bente, additional, and Lindström, Ulf, additional

Published
2022
Full Text
View/download PDF

20. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

Author

Christiansen, Sara Nysom, primary, Ørnbjerg, Lykke Midtbøll, additional, Rasmussen, Simon Horskjær, additional, Loft, Anne Gitte, additional, Askling, Johan, additional, Iannone, Florenzo, additional, Zavada, Jakub, additional, Michelsen, Brigitte, additional, Nissen, Michael, additional, Onen, Fatos, additional, Santos, Maria Jose, additional, Pombo-Suarez, Manuel, additional, Relas, Heikki, additional, Macfarlane, Gary J, additional, Tomsic, Matija, additional, Codreanu, Catalin, additional, Gudbjornsson, Bjorn, additional, Van der Horst-Bruinsma, Irene, additional, Di Giuseppe, Daniela, additional, Glintborg, Bente, additional, Gremese, Elisa, additional, Pavelka, Karel, additional, Kristianslund, Eirik Klami, additional, Ciurea, Adrian, additional, Akkoc, Nurullah, additional, Barcelos, Anabela, additional, Sánchez-Piedra, Carlos, additional, Peltomaa, Ritva, additional, Jones, Gareth T, additional, Rotar, Ziga, additional, Ionescu, Ruxandra, additional, Grondal, Gerdur, additional, Van de Sande, Marleen G H, additional, Laas, Karin, additional, Østergaard, Mikkel, additional, and Hetland, Merete L, additional

Published
2021
Full Text
View/download PDF

23. Validation of the classification criteria for cryoglobulinaemic vasculitis

Author

Quartuccio, Luca, Isola, Miriam, Corazza, Laura, Ramos-Casals, Manuel, Retamozo, Soledad, Ragab, Gaafar Mohamed, Zoheir, Mostafa Naguib, El-Menyawi, Manal Abdel-Moneim, Salem, Mohamed Nabil, Sansonno, Domenico, Ferraccioli, Gianfranco, Gremese, Elisa, Tzioufas, Athanasios, Voulgarelis, Michael, Vassilopoulos, Dimitris, Scarpato, Salvatore, Pipitone, Nicolò, Salvarani, Carlo, Guillevin, Loic, Terrier, Benjamin, Cacoub, Patrice, Filippini, Davide, Saccardo, Francesco, Gabrielli, Armando, Fraticelli, Paolo, Sebastiani, Marco, Tomsic, Matija, Tavoni, Antonio, Mazzaro, Cesare, Pioltelli, Pietro, Nishimoto, Norihiro, Scaini, Patrizia, Zignego, Anna Linda, Ferri, Clodoveo, Monti, Giuseppe, Pietrogrande, Maurizio, Bombardieri, Stefano, Galli, Massimo, and De Vita, Salvatore

Published
2014
Full Text
View/download PDF

24. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response.

Author

Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Rasmussen, Simon Horskjær, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fatos, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J, Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Horst-Bruinsma, Irene Van der, Giuseppe, Daniela Di, and Glintborg, Bente

Subjects
PSORIATIC arthritis, STATISTICS, TIME, ANTI-inflammatory agents, SPONDYLOARTHROPATHIES, DESCRIPTIVE statistics, RESEARCH funding, DATA analysis, DISEASE remission, LONGITUDINAL method
Abstract

Objectives To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. Methods Prospectively collected data on bio-naïve axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999–2008), B (2009–2014) and C (2015–2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. Results In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. Conclusion Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response

Author

Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Horskjær Rasmussen, Simon, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fato, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J, Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Van der Horst-Bruinsma, Irene, Di Giuseppe, Daniela, Glintborg, Bente, Gremese, Elisa, Pavelka, Karel, Kristianslund, Eirik Klami, Ciurea, Adrian, Akkoc, Nurullah, Barcelos, Anabela, Sánchez-Piedra, Carlo, Peltomaa, Ritva, Jones, Gareth T, Rotar, Ziga, Ionescu, Ruxandra, Grondal, Gerdur, Van de Sande, Marleen G H, Laas, Karin, Østergaard, Mikkel, Hetland, Merete L, Gremese, Elisa (ORCID:0000-0002-2248-1058), Christiansen, Sara Nysom, Ørnbjerg, Lykke Midtbøll, Horskjær Rasmussen, Simon, Loft, Anne Gitte, Askling, Johan, Iannone, Florenzo, Zavada, Jakub, Michelsen, Brigitte, Nissen, Michael, Onen, Fato, Santos, Maria Jose, Pombo-Suarez, Manuel, Relas, Heikki, Macfarlane, Gary J, Tomsic, Matija, Codreanu, Catalin, Gudbjornsson, Bjorn, Van der Horst-Bruinsma, Irene, Di Giuseppe, Daniela, Glintborg, Bente, Gremese, Elisa, Pavelka, Karel, Kristianslund, Eirik Klami, Ciurea, Adrian, Akkoc, Nurullah, Barcelos, Anabela, Sánchez-Piedra, Carlo, Peltomaa, Ritva, Jones, Gareth T, Rotar, Ziga, Ionescu, Ruxandra, Grondal, Gerdur, Van de Sande, Marleen G H, Laas, Karin, Østergaard, Mikkel, Hetland, Merete L, and Gremese, Elisa (ORCID:0000-0002-2248-1058)

Abstract

Objectives To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naive axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating TNF inhibitor (TNFi) treatment. Methods Prospectively collected data on bio-naive axSpA and PsA patients from routine care in 15 European countries were pooled. Three cohorts were defined according to year of TNFi initiation: A (1999-2008), B (2009-2014) and C (2015-2018). Retention, remission and response rates were assessed at 6, 12 and 24 months. Results In total, 27 149 axSpA and 17 446 PsA patients were included. Cohort A patients had longer disease duration compared with B and C. In axSpA, cohort A had the largest proportion of male and HLA-B27 positive patients. In PsA, baseline disease activity was highest in cohort A. Retention rates in axSpA/PsA were highest in cohort A and differed only slightly between B and C. For all cohorts, disease activity decreased markedly from 0 to 6 months. In axSpA, disease activity at 24 months was highest in cohort A, where also remission and response rates were lowest. In PsA, remission rates at 6 and 12 months tended to be lowest in cohort A. Response rates were at all time points comparable across cohorts, and less between-cohort disease activity differences were seen at 24 months. Conclusion Our findings indicate that over the past decades, clinicians have implemented more aggressive treatment strategies in spondyloarthritis. This was illustrated by shorter disease duration at treatment initiation, decreased retention rates and higher remission rates during recent years.

Published
2021

26. Structural properties of pure simple alcohols from ethanol, propanol, butanol, pentanol, to hexanol: Comparing Monte Carlo simulations with experimental SAXS data

Author

Tomsic, Matija, Jamnik, Andrej, Fritz-Popovski, Gerhard, Glatter, Otto, and Vlcek, Lukas

Subjects
Alcohols -- Chemical properties, Alcohols -- Structure, Monte Carlo method -- Usage, Intermolecular forces -- Research, Chemicals, plastics and rubber industries
Abstract

The configurational-bias Monte Carlo (MC) simulations and the small-angle X-ray scattering (SAXS) data are used together to analyze the structural properties of various pure simple alcohols, including ethanol, propanol, butanol, pentanol and hexanol. The study provides an insight in the binary and ternary microemulsion systems of the nonionic surfactant, which can be further employed to examine the structure of various alcohol-rich alcohol/water mixtures.

Published
2007

28. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

Author

Michelsen, Brigitte, primary, Lindström, Ulf, additional, Codreanu, Catalin, additional, Ciurea, Adrian, additional, Zavada, Jakub, additional, Loft, Anne Gitte, additional, Pombo-Suarez, Manuel, additional, Onen, Fatos, additional, Kvien, Tore K, additional, Rotar, Ziga, additional, Santos, Maria Jose, additional, Iannone, Florenzo, additional, Hokkanen, Anna-Mari, additional, Gudbjornsson, Bjorn, additional, Askling, Johan, additional, Ionescu, Ruxandra, additional, Nissen, Michael J, additional, Pavelka, Karel, additional, Sanchez-Piedra, Carlos, additional, Akar, Servet, additional, Sexton, Joseph, additional, Tomsic, Matija, additional, Santos, Helena, additional, Sebastiani, Marco, additional, Österlund, Jenny, additional, Geirsson, Arni Jon, additional, Macfarlane, Gary, additional, van der Horst-Bruinsma, Irene, additional, Georgiadis, Stylianos, additional, Brahe, Cecilie Heegaard, additional, Ørnbjerg, Lykke Midtbøll, additional, Hetland, Merete Lund, additional, and Østergaard, Mikkel, additional

Published
2020
Full Text
View/download PDF

30. POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION

Author

Iannone, Florenzo, Hetland, Merete L., Ostergaard, Mikkel, Krogh, Niels Steen, Hyldstrup, Lise, Macfarlane, Gary, van der Horst-Bruinsma, Irene, Favalli, Ennio Giulio, Geirsson, Arni Jon, Trokovic, Nina, Santos, Helena, Tomsic, Matija, Kristianslund, Eirik, Akar, Servet, Sanchez-Piedra, Carlos, Pavelka, Karel, Nissen, Michael, Ionescu, Ruxandra, Di Giuseppe, Daniela, Gudbjornsson, Bjorn, Eklund, Kari, Santos, Maria Jose, Rotar, Ziga, Sexton, Joe, ÖNEN, FATOŞ, Pombo-Suarez, Manuel, Mann, Herman, Loft, Anne Gitte, Ciurea, Adrian, Codreanu, Catalin, Askling, Johan, Brahe, Cecilie Heegaard, and Michelsen, Brigitte

Published
2019

31. DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE - RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION

Author

Mann, Herman, Kristianslund, Eirik, Nissen, Michael, Jacobsson, Lennart T. H., Ornbjerg, Lykke, Brahe, Cecilie Heegaard, Hetland, Merete L., Ostergaard, Mikkel, Krogh, Niels Steen, Hyldstrup, Lise, Iannone, Florenzo, Macfarlane, Gary, van der Horst-Bruinsma, Irene, van de Sande, Marleen, Loft, Anne Gitte, Ionescu, Ruxandra, Can, Gercek, Love, Thorvardur Jon, Tomsic, Matija, Eklund, Kari, Sanchez-Piedra, Carlos, Barcelos, Anabela, Pavelka, Karel, Sexton, Joe, Moeller, Burkhard, Lindstrom, Ulf, Codreanu, Catalin, Gudbjornsson, Bjorn, ÖNEN, FATOŞ, Rotar, Ziga, Nordstrom, Dan, Pombo-Suarez, Manuel, and Santos, Maria Jose

Published
2019

33. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment:routine care data from 13 registries in the EuroSpA collaboration

Author

Michelsen, Brigitte, Lindström, Ulf, Codreanu, Catalin, Ciurea, Adrian, Zavada, Jakub, Loft, Anne Gitte, Pombo-Suarez, Manuel, Onen, Fatos, Kvien, Tore K., Rotar, Ziga, Santos, Maria Jose, Iannone, Florenzo, Hokkanen, Anna Mari, Gudbjornsson, Bjorn, Askling, Johan, Ionescu, Ruxandra, Nissen, Michael J., Pavelka, Karel, Sanchez-Piedra, Carlos, Akar, Servet, Sexton, Joseph, Tomsic, Matija, Santos, Helena, Sebastiani, Marco, Österlund, Jenny, Geirsson, Arni Jon, Macfarlane, Gary, van der Horst-Bruinsma, Irene, Georgiadis, Stylianos, Brahe, Cecilie Heegaard, Ørnbjerg, Lykke Midtbøll, Hetland, Merete Lund, Østergaard, Mikkel, Michelsen, Brigitte, Lindström, Ulf, Codreanu, Catalin, Ciurea, Adrian, Zavada, Jakub, Loft, Anne Gitte, Pombo-Suarez, Manuel, Onen, Fatos, Kvien, Tore K., Rotar, Ziga, Santos, Maria Jose, Iannone, Florenzo, Hokkanen, Anna Mari, Gudbjornsson, Bjorn, Askling, Johan, Ionescu, Ruxandra, Nissen, Michael J., Pavelka, Karel, Sanchez-Piedra, Carlos, Akar, Servet, Sexton, Joseph, Tomsic, Matija, Santos, Helena, Sebastiani, Marco, Österlund, Jenny, Geirsson, Arni Jon, Macfarlane, Gary, van der Horst-Bruinsma, Irene, Georgiadis, Stylianos, Brahe, Cecilie Heegaard, Ørnbjerg, Lykke Midtbøll, Hetland, Merete Lund, and Østergaard, Mikkel

Abstract

OBJECTIVES: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. METHODS: Real-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)). RESULTS: We included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70-93%, 12-month: 53-86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness. CONCLUSIONS: In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, sec

Published
2020

34. EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

Author

Meisters, Rachelle, Putrik, Polina, Ramiro, Sofia, Hifinger, Monika, Keszei, Andras P., van Eijk-Hustings, Yvonne, Woolf, Anthony D., Smolen, Josef S., Stamm, Tanja A., Stoffer-Marx, Michaela, Uhlig, Till, Moe, Rikke Helene, de Wit, Maarten, Tafaj, Argjend, Mukuchyan, Vahan, Studenic, Paul, Verschueren, Patrick, Shumnalieva, Russka, Charalambous, Paraskevi, Vencovsky, Jiri, Varvouni, Melpomeni, Kull, Mart, Puolakka, Kari, Gossec, Laure, Gobejishvili, Nino, Detert, Jacqueline, Sidiropoulos, Prodromos, Pentek, Marta, Kane, David, Scire, Carlo Alberto, Arad, Uri, Andersone, Daina, van de Laar, Mart, van der Helm-van Mil, Annette, Gluszko, Piotr, Cunha-Miranda, Luis, Berghea, Florian, Damjanov, Nemanja S., Tomsic, Matija, Carmona, Loreto, Turesson, Carl, Ciurea, Adrian, Shukurova, Surayo, Inanc, Nevsun, Verstappen, Suzanne M. M., Boonen, Annelies, Working group, Meisters, Rachelle, Putrik, Polina, Ramiro, Sofia, Hifinger, Monika, Keszei, Andras P., van Eijk-Hustings, Yvonne, Woolf, Anthony D., Smolen, Josef S., Stamm, Tanja A., Stoffer-Marx, Michaela, Uhlig, Till, Moe, Rikke Helene, de Wit, Maarten, Tafaj, Argjend, Mukuchyan, Vahan, Studenic, Paul, Verschueren, Patrick, Shumnalieva, Russka, Charalambous, Paraskevi, Vencovsky, Jiri, Varvouni, Melpomeni, Kull, Mart, Puolakka, Kari, Gossec, Laure, Gobejishvili, Nino, Detert, Jacqueline, Sidiropoulos, Prodromos, Pentek, Marta, Kane, David, Scire, Carlo Alberto, Arad, Uri, Andersone, Daina, van de Laar, Mart, van der Helm-van Mil, Annette, Gluszko, Piotr, Cunha-Miranda, Luis, Berghea, Florian, Damjanov, Nemanja S., Tomsic, Matija, Carmona, Loreto, Turesson, Carl, Ciurea, Adrian, Shukurova, Surayo, Inanc, Nevsun, Verstappen, Suzanne M. M., Boonen, Annelies, and Working group

Abstract

Objective As part of European League against Rheumatism (EULAR)/European Musculoskeletal Conditions Surveillance and Information Network, 20 user-focused standards of care (SoCs) for rheumatoid arthritis (RA) addressing 16 domains of care were developed. This study aimed to explore gaps in implementation of these SoCs across Europe.Methods Two cross-sectional surveys on the importance, level of and barriers (patients only) to implementation of each SoC (0-10, 10 highest) were designed to be conducted among patients and rheumatologists in 50 European countries. Care gaps were calculated as the difference between the actual and maximum possible score for implementation (ie, 10) multiplied by the care importance score, resulting in care gaps (0-100, maximal gap). Factors associated with the problematic care gaps (ie, gap >= 30 and importance >= 6 and implementation= 6) were further analysed in multilevel logistic regression models.Results Overall, 26 and 31 countries provided data from 1873 patients and 1131 rheumatologists, respectively. 19 out of 20 SoCs were problematic from the perspectives of more than 20% of patients, while this was true for only 10 SoCs for rheumatologists. Rheumatologists in countries with lower gross domestic product and non-European Union countries were more likely to report problematic gaps in 15 of 20 SoCs, while virtually no differences were observed among patients. Lack of relevance of some SoCs (71%) and limited time of professionals (66%) were the most frequent implementation barriers identified by patients.Conclusions Many problematic gaps were reported across several essential aspects of RA care. More efforts need to be devoted to implementation of EULAR SoCs.

Published
2020

36. Secukinumab effectiveness in 1134 patients with psoriatic arthritis treated in routine clinical practice in 11 European countries in the EuroSpA research collaboration network

Author

Michelsen, Brigitte, Diguiseppe, Daniela, Loft, Anne Gitte, Pombo-Suarez, Manuel, Mann, Herman, Rotar, Ziga, Iannone, Florenzo, Kvien, Tore, Santos, Maria Jose, Eklund, Kari K., Gudbjornsson, Bjorn, Codreanu, Catalin, Yilmaz, Sema, Askling, Johan, Sanchez-Piedra, Carlos, Pavelka, Karel, Tomsic, Matija, Conti, Fabrizio, Sexton, Joe, Santos, Helena, Trokovic, Nina, Love, Thorvardur J., Ionescu, Ruxandra, Pehlivan, Yavuz, Nissen, Michael J., Gary Macfarlane, Horst-Bruinsma, Irene, Georgiadis, Stylianos, Ornbjerg, Lykke Midtboll, Brahe, Cecilie Heegaard, Hetland, Merete Lund, Ostergaard, Mikkel, Selçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, and Yılmaz, Sema.

Subjects
psoriatic arthritis treated, Secukinumab
Abstract

WOS: 000507466902413, …

Published
2019

39. Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study

Author

Vitali, Claudio, Bombardieri, Stefano, Moutsopoulos, Haralampos M., Coll, Joaquin, Gerli, Roberto, Hatron, Pierre Y., Kater, Louis, Konttinen, Yrjo T., Manthorpe, Rolf, Meyer, Olivier, Mosca, Marta, Ostuni, Pierantonio, Pellerito, Raffaele A., Pennec, Yvon, Porter, Stephen R., Richards, Andrea, Sauvezie, Bernard, Schiodt, Morten, Sciuto, Maria, Shoenfeld, Yehuda, Skopouli, Fotini N., Smolen, Josef S., Soromenho, Francisco, Tishler, Moshe, Tomsic, Matija, van de Merwe, Joop P., Yeoman, Christine M., and Wattiaux, Marie J.

Published
1996

40. DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS DEPEND ON THE REASON FROM WITHDRAWAL FROM THE PREVIOUS TREATMENT?:RESULTS FROM THE EUROSPA RESEARCH COLLABORATION

Author

Ørnbjerg, Lykke, Brahe, Cecilie Heegaard, Loft, Anne Gitte, Askling, Johan, Ciurea, Adrian, Mann, Heřman, Akar, Servet, Kristianslund, Eirik, Nordström, Dan, Santos, Maria Jose, Codreanu, Catalin, Pombo-suarez, Manuel, Rotar, Ziga, Gudbjornsson, Björn, Giuseppe, Daniela Di, Nissen, Michael, Pavelka, Karel, Senel, Soner, Sexton, Joe, Eklund, Kari, Barcelos, Anabela, Ionescu, Ruxandra, Sánchez-piedra, Carlos, Tomsic, Matija, Geirsson, Arni Jon, Horst-bruinsma, Irene Van Der, Macfarlane, Gary, Iannone, Florenzo, Michelsen, Brigitte, Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete L., Østergaard, Mikkel, Ørnbjerg, Lykke, Brahe, Cecilie Heegaard, Loft, Anne Gitte, Askling, Johan, Ciurea, Adrian, Mann, Heřman, Akar, Servet, Kristianslund, Eirik, Nordström, Dan, Santos, Maria Jose, Codreanu, Catalin, Pombo-suarez, Manuel, Rotar, Ziga, Gudbjornsson, Björn, Giuseppe, Daniela Di, Nissen, Michael, Pavelka, Karel, Senel, Soner, Sexton, Joe, Eklund, Kari, Barcelos, Anabela, Ionescu, Ruxandra, Sánchez-piedra, Carlos, Tomsic, Matija, Geirsson, Arni Jon, Horst-bruinsma, Irene Van Der, Macfarlane, Gary, Iannone, Florenzo, Michelsen, Brigitte, Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete L., and Østergaard, Mikkel

Published
2019

41. TREATMENT RESPONSE AND DRUG RETENTION RATES IN 23,956 BIOLOGIC-NAÏVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS INITIATING TNFI TREATMENT:ROUTINE CARE DATA FROM 12 REGISTRIES IN THE EUROSPA COLLABORATION

Author

Ørnbjerg, Lykke, Heegaard Brahe, Cecilie, Loft, Anne Gitte, Askling, Johan, Ciurea, Adrian, Mann, Heřman, Onen, Fatos, Kristianslund, Eirik, Nordström, Dan, Santos, Maria José, Codreanu, Catalin, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Björn, Giuseppe, Daniela Di, Nissen, Michael, Pavelka, Karel, Birlik, Merih, Sexton, Joe, Eklund, Karin, Barcelos, Anabela, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Tomsic, Matija, Geirsson, Arni Jon, Horst-bruinsma, Irene Van Der, Jones, Gareth T., Iannone, Florenzo, Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete L., Østergaard, Mikkel, Ørnbjerg, Lykke, Heegaard Brahe, Cecilie, Loft, Anne Gitte, Askling, Johan, Ciurea, Adrian, Mann, Heřman, Onen, Fatos, Kristianslund, Eirik, Nordström, Dan, Santos, Maria José, Codreanu, Catalin, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Björn, Giuseppe, Daniela Di, Nissen, Michael, Pavelka, Karel, Birlik, Merih, Sexton, Joe, Eklund, Karin, Barcelos, Anabela, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Tomsic, Matija, Geirsson, Arni Jon, Horst-bruinsma, Irene Van Der, Jones, Gareth T., Iannone, Florenzo, Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete L., and Østergaard, Mikkel

Published
2019

42. High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients:Data from the EuroSpA Research Collaboration Network

Author

Michelsen, Brigitte, Ørnbjerg, Lykke Midtbøll, Mann, Herman, Kvien, Tore, Nissen, Michael J., Santos, Maria José, Nordström, Dan, Jacobsson, Lennart, Rotar, Ziga, Gudbjornsson, Bjorn, Koca, Süleyman Serdar, Codreanu, Catalin, Pombo-Suarez, Manuel, Horst-Bruinsma, Irene Van Der, Loft, Anne Gitte, Pavelka, Karel, Kristianslund, Eirik, Moeller, Burkhard, Vieira-Sousa, Elsa, Hokkanen, Anna Mari, Lindström, Ulf, Tomsic, Matija, Love, Thorvardur Jon, Tufan, Abdurrahman, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Sande, Marleen Van De, Macfarlane, Gary, Iannone, Florenzo, Hyldstrup, Lise, Østergaard, Mikkel, Hetland, Merete Lund, Michelsen, Brigitte, Ørnbjerg, Lykke Midtbøll, Mann, Herman, Kvien, Tore, Nissen, Michael J., Santos, Maria José, Nordström, Dan, Jacobsson, Lennart, Rotar, Ziga, Gudbjornsson, Bjorn, Koca, Süleyman Serdar, Codreanu, Catalin, Pombo-Suarez, Manuel, Horst-Bruinsma, Irene Van Der, Loft, Anne Gitte, Pavelka, Karel, Kristianslund, Eirik, Moeller, Burkhard, Vieira-Sousa, Elsa, Hokkanen, Anna Mari, Lindström, Ulf, Tomsic, Matija, Love, Thorvardur Jon, Tufan, Abdurrahman, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Sande, Marleen Van De, Macfarlane, Gary, Iannone, Florenzo, Hyldstrup, Lise, Østergaard, Mikkel, and Hetland, Merete Lund

Published
2019

43. Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care:Was PRO Remission Achieved? Results from the EuroSpA Collaboration

Author

Ørnbjerg, Lykke Midtbøll, Jacobsson, Lennart, Loft, Anne Gitte, Iannone, Florenzo, Nissen, Michael J., Kristianslund, Eirik, Mann, Herman, Santos, Maria José, Pombo-Suarez, Manuel, Eklund, Karin, Rotar, Ziga, Gudbjornsson, Bjorn, Öztürk, Mehmet Akif, Codreanu, Catalin, Sande, Marleen Van De, Wallman, Johan, Favalli, Ennio Giulio, Moeller, Burkhard, Sexton, Joe, Pavelka, Karel, Vieira-Sousa, Elsa, Sanchez-Piedra, Carlos, Trokovic, Nina, Tomsic, Matija, Love, Thorvardur Jon, Cefle, Ayşe, Ionescu, Ruxandra, Horst-Bruinsma, Irene Van Der, Jones, Gareth, Heegaard Brahe, Cecilie, Hetland, Merete Lund, Østergaard, Mikkel, Ørnbjerg, Lykke Midtbøll, Jacobsson, Lennart, Loft, Anne Gitte, Iannone, Florenzo, Nissen, Michael J., Kristianslund, Eirik, Mann, Herman, Santos, Maria José, Pombo-Suarez, Manuel, Eklund, Karin, Rotar, Ziga, Gudbjornsson, Bjorn, Öztürk, Mehmet Akif, Codreanu, Catalin, Sande, Marleen Van De, Wallman, Johan, Favalli, Ennio Giulio, Moeller, Burkhard, Sexton, Joe, Pavelka, Karel, Vieira-Sousa, Elsa, Sanchez-Piedra, Carlos, Trokovic, Nina, Tomsic, Matija, Love, Thorvardur Jon, Cefle, Ayşe, Ionescu, Ruxandra, Horst-Bruinsma, Irene Van Der, Jones, Gareth, Heegaard Brahe, Cecilie, Hetland, Merete Lund, and Østergaard, Mikkel

Published
2019

44. POOLED 6-MONTH TREATMENT OUTCOMES AND DRUG RETENTION RATES IN 1556 PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH SECUKINUMAB IN ROUTINE CLINICAL PRACTICE IN 12 EUROPEAN COUNTRIES IN THE EUROSPA RESEARCH COLLABORATION

Author

Michelsen, Brigitte, Brahe, Cecilie Heegaard, Askling, Johan, Codreanu, Catalin, Ciurea, Adrian, Loft, Anne Gitte, Mann, Heřman, Pombo-suarez, Manuel, Onen, Fatos, Sexton, Joe, Rotar, Ziga, Santos, Maria Jose, Eklund, Kari, Gudbjornsson, Björn, Iannone, Florenzo, Giuseppe, Daniela Di, Ionescu, Ruxandra, Nissen, Michael, Pavelka, Karel, Sánchez-piedra, Carlos, Akar, Servet, Kristianslund, Eirik, Tomsic, Matija, Santos, Helena, Trokovic, Nina, Geirsson, Arni Jon, Favalli, Ennio Giulio, Horst-bruinsma, Irene Van Der, Macfarlane, Gary, Hyldstrup, Lise, Krogh, Niels Steen, Østergaard, Mikkel, Hetland, Merete L., Michelsen, Brigitte, Brahe, Cecilie Heegaard, Askling, Johan, Codreanu, Catalin, Ciurea, Adrian, Loft, Anne Gitte, Mann, Heřman, Pombo-suarez, Manuel, Onen, Fatos, Sexton, Joe, Rotar, Ziga, Santos, Maria Jose, Eklund, Kari, Gudbjornsson, Björn, Iannone, Florenzo, Giuseppe, Daniela Di, Ionescu, Ruxandra, Nissen, Michael, Pavelka, Karel, Sánchez-piedra, Carlos, Akar, Servet, Kristianslund, Eirik, Tomsic, Matija, Santos, Helena, Trokovic, Nina, Geirsson, Arni Jon, Favalli, Ennio Giulio, Horst-bruinsma, Irene Van Der, Macfarlane, Gary, Hyldstrup, Lise, Krogh, Niels Steen, Østergaard, Mikkel, and Hetland, Merete L.

Published
2019

45. REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE:POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK

Author

Michelsen, Brigitte, Brahe, Cecilie Heegaard, Jacobsson, Lennart T.h., Nissen, Michael, Pombo-suarez, Manuel, Mann, Heřman, Rotar, Ziga, Sexton, Joe, Santos, Maria Jose, Nordström, Dan, Codreanu, Catalin, Gudbjornsson, Björn, Yilmaz, Sema, Iannone, Florenzo, Lindström, Ulf, Loft, Anne Gitte, Moeller, Burkhard, Sánchez-piedra, Carlos, Pavelka, Karel, Tomsic, Matija, Kristianslund, Eirik, Santos, Helena, Hokkanen, Anna-mari, Ionescu, Ruxandra, Love, Thorvardur Jon, Pehlivan, Yavuz, Sebastiani, Marco, Jones, Gareth T., Van Der Horst-bruinsma, Irene, Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete L., Østergaard, Mikkel, Michelsen, Brigitte, Brahe, Cecilie Heegaard, Jacobsson, Lennart T.h., Nissen, Michael, Pombo-suarez, Manuel, Mann, Heřman, Rotar, Ziga, Sexton, Joe, Santos, Maria Jose, Nordström, Dan, Codreanu, Catalin, Gudbjornsson, Björn, Yilmaz, Sema, Iannone, Florenzo, Lindström, Ulf, Loft, Anne Gitte, Moeller, Burkhard, Sánchez-piedra, Carlos, Pavelka, Karel, Tomsic, Matija, Kristianslund, Eirik, Santos, Helena, Hokkanen, Anna-mari, Ionescu, Ruxandra, Love, Thorvardur Jon, Pehlivan, Yavuz, Sebastiani, Marco, Jones, Gareth T., Van Der Horst-bruinsma, Irene, Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete L., and Østergaard, Mikkel

Published
2019

46. HIGH BASELINE PATIENT’S COMPARED WITH EVALUATOR’S GLOBAL ASSESSMENT IS ASSOCIATED WITH LOWER RETENTION AND REMISSION RATES OF FIRST TNF INHIBITOR IN AXSPA PATIENTS:DATA FROM THE EUROSPA COLLABORATION

Author

Michelsen, Brigitte, Ørnbjerg, Lykke, Loft, Anne Gitte, Sexton, Joseph, Ciurea, Adrian, Mann, Heřman, Eklund, Kari, Yazici, Ayten, Santos, Maria Jose, Askling, Johan, Rotar, Ziga, Gudbjornsson, Björn, Pombo-suarez, Manuel, Codreanu, Catalin, Horst-bruinsma, Irene Van Der, Kristianslund, Eirik, Nissen, Michael, Pavelka, Karel, Trokovic, Nina, Inanc, Nevsun, Vieira-sousa, Elsa, Giuseppe, Daniela Di, Tomsic, Matija, Geirsson, Arni Jon, Ionescu, Ruxandra, Sande, Marleen Van De, Iannone, Florenzo, Sánchez-piedra, Carlos, Jones, Gareth T., Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete L., Østergaard, Mikkel, Michelsen, Brigitte, Ørnbjerg, Lykke, Loft, Anne Gitte, Sexton, Joseph, Ciurea, Adrian, Mann, Heřman, Eklund, Kari, Yazici, Ayten, Santos, Maria Jose, Askling, Johan, Rotar, Ziga, Gudbjornsson, Björn, Pombo-suarez, Manuel, Codreanu, Catalin, Horst-bruinsma, Irene Van Der, Kristianslund, Eirik, Nissen, Michael, Pavelka, Karel, Trokovic, Nina, Inanc, Nevsun, Vieira-sousa, Elsa, Giuseppe, Daniela Di, Tomsic, Matija, Geirsson, Arni Jon, Ionescu, Ruxandra, Sande, Marleen Van De, Iannone, Florenzo, Sánchez-piedra, Carlos, Jones, Gareth T., Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete L., and Østergaard, Mikkel

Published
2019

47. DOES DISCORDANCE BETWEEN BASELINE PATIENT’S AND EVALUATOR’S GLOBAL ASSESSMENT OF DISEASE ACTIVITY IMPACT RETENTION AND REMISSION RATES OF TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS?:DATA FROM THE EUROSPA RESEARCH COLLABORATION

Author

Michelsen, Brigitte, Ørnbjerg, Lykke, Mann, Heřman, Sexton, Joseph, Nissen, Michael, Santos, Maria Jose, Nordström, Dan, Jacobsson, Lennart T.h., Rotar, Ziga, Gudbjornsson, Björn, Koca, Süleyman Serdar, Codreanu, Catalin, Pombo-suarez, Manuel, Horst-bruinsma, Irene Van Der, Loft, Anne Gitte, Pavelka, Karel, Kristianslund, Eirik, Moeller, Burkhard, Vieira-sousa, Elsa, Hokkanen, Anna-mari, Lindström, Ulf, Tomsic, Matija, Love, Thorvardur Jon, Goker, Berna, Ionescu, Ruxandra, Sánchez-piedra, Carlos, Sande, Marleen Van De, Macfarlane, Gary, Iannone, Florenzo, Hyldstrup, Lise, Krogh, Niels Steen, Østergaard, Mikkel, Hetland, Merete L., Michelsen, Brigitte, Ørnbjerg, Lykke, Mann, Heřman, Sexton, Joseph, Nissen, Michael, Santos, Maria Jose, Nordström, Dan, Jacobsson, Lennart T.h., Rotar, Ziga, Gudbjornsson, Björn, Koca, Süleyman Serdar, Codreanu, Catalin, Pombo-suarez, Manuel, Horst-bruinsma, Irene Van Der, Loft, Anne Gitte, Pavelka, Karel, Kristianslund, Eirik, Moeller, Burkhard, Vieira-sousa, Elsa, Hokkanen, Anna-mari, Lindström, Ulf, Tomsic, Matija, Love, Thorvardur Jon, Goker, Berna, Ionescu, Ruxandra, Sánchez-piedra, Carlos, Sande, Marleen Van De, Macfarlane, Gary, Iannone, Florenzo, Hyldstrup, Lise, Krogh, Niels Steen, Østergaard, Mikkel, and Hetland, Merete L.

Published
2019

48. DRUG RETENTION AND REMISSION RATES IN 14,261 BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS STARTING TNF INHIBITOR TREATMENT IN ROUTINE CARE – RESULTS FROM 12 REGISTRIES IN THE EUROSPA RESEARCH COLLABORATION

Author

Brahe, Cecilie Heegaard, Ørnbjerg, Lykke, Jacobsson, Lennart T.h., Nissen, Michael, Kristianslund, Eirik, Mann, Heřman, Santos, Maria Jose, Pombo-suarez, Manuel, Nordström, Dan, Rotar, Ziga, Gudbjornsson, Björn, Onen, Fatos, Codreanu, Catalin, Lindström, Ulf, Moeller, Burkhard, Sexton, Joe, Pavelka, Karel, Barcelos, Anabela, Sánchez-piedra, Carlos, Eklund, Kari, Tomsic, Matija, Love, Thorvardur Jon, Can, Gerçek, Ionescu, Ruxandra, Loft, Anne Gitte, Sande, Marleen Van De, Horst-bruinsma, Irene Van Der, Macfarlane, Gary, Iannone, Florenzo, Hyldstrup, Lise, Krogh, Niels Steen, Østergaard, Mikkel, Hetland, Merete L., Brahe, Cecilie Heegaard, Ørnbjerg, Lykke, Jacobsson, Lennart T.h., Nissen, Michael, Kristianslund, Eirik, Mann, Heřman, Santos, Maria Jose, Pombo-suarez, Manuel, Nordström, Dan, Rotar, Ziga, Gudbjornsson, Björn, Onen, Fatos, Codreanu, Catalin, Lindström, Ulf, Moeller, Burkhard, Sexton, Joe, Pavelka, Karel, Barcelos, Anabela, Sánchez-piedra, Carlos, Eklund, Kari, Tomsic, Matija, Love, Thorvardur Jon, Can, Gerçek, Ionescu, Ruxandra, Loft, Anne Gitte, Sande, Marleen Van De, Horst-bruinsma, Irene Van Der, Macfarlane, Gary, Iannone, Florenzo, Hyldstrup, Lise, Krogh, Niels Steen, Østergaard, Mikkel, and Hetland, Merete L.

Published
2019

49. DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS DEPEND ON THE REASON FOR WITHDRAWAL FROM THE PREVIOUS TREATMENT?:RESULTS FROM THE EUROSPA RESEARCH COLLABORATION

Author

Brahe, Cecilie Heegaard, Ørnbjerg, Lykke, Jacobsson, Lennart T.h., Nissen, Michael, Kristianslund, Eirik, Mann, Heřman, Santos, Maria Jose, Pombo-suarez, Manuel, Nordström, Dan, Rotar, Ziga, Gudbjornsson, Björn, Dalkiliç, Ediz, Codreanu, Catalin, Loft, Anne Gitte, Lindström, Ulf, Moeller, Burkhard, Sexton, Joe, Pavelka, Karel, Barcelos, Anabela, Sánchez-piedra, Carlos, Eklund, Kari, Tomsic, Matija, Love, Thorvardur Jon, Sari, Ismail, Ionescu, Ruxandra, Sande, Marleen Van De, Horst-bruinsma, Irene Van Der, Jones, Gareth T, Iannone, Florenzo, Michelsen, Brigitte, Hyldstrup, Lise, Krogh, Niels Steen, Østergaard, Mikkel, Hetland, Merete L., Brahe, Cecilie Heegaard, Ørnbjerg, Lykke, Jacobsson, Lennart T.h., Nissen, Michael, Kristianslund, Eirik, Mann, Heřman, Santos, Maria Jose, Pombo-suarez, Manuel, Nordström, Dan, Rotar, Ziga, Gudbjornsson, Björn, Dalkiliç, Ediz, Codreanu, Catalin, Loft, Anne Gitte, Lindström, Ulf, Moeller, Burkhard, Sexton, Joe, Pavelka, Karel, Barcelos, Anabela, Sánchez-piedra, Carlos, Eklund, Kari, Tomsic, Matija, Love, Thorvardur Jon, Sari, Ismail, Ionescu, Ruxandra, Sande, Marleen Van De, Horst-bruinsma, Irene Van Der, Jones, Gareth T, Iannone, Florenzo, Michelsen, Brigitte, Hyldstrup, Lise, Krogh, Niels Steen, Østergaard, Mikkel, and Hetland, Merete L.

Published
2019

50. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment:routine care data from 12 registries in the EuroSpA collaboration

Author

Ørnbjerg, Lykke Midtbøll, Brahe, Cecilie Heegaard, Askling, Johan, Ciurea, Adrian, Mann, Herman, Onen, Fatos, Kristianslund, Eirik Klami, Nordström, Dan, Santos, Maria Jose, Codreanu, Catalin, Gómez-Reino, Juan, Rotar, Ziga, Gudbjornsson, Bjorn, Di Giuseppe, Daniela, Nissen, Michael J., Pavelka, Karel, Birlik, Merih, Kvien, Tore, Eklund, Kari Kalervo, Barcelos, Anabela, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Tomsic, Matija, Geirsson, Árni Jón, Loft, Anne Gitte, Van Der Horst-Bruinsma, Irene, Jones, Gareth, Iannone, Florenzo, Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete Lund, Østergaard, Mikkel, Ørnbjerg, Lykke Midtbøll, Brahe, Cecilie Heegaard, Askling, Johan, Ciurea, Adrian, Mann, Herman, Onen, Fatos, Kristianslund, Eirik Klami, Nordström, Dan, Santos, Maria Jose, Codreanu, Catalin, Gómez-Reino, Juan, Rotar, Ziga, Gudbjornsson, Bjorn, Di Giuseppe, Daniela, Nissen, Michael J., Pavelka, Karel, Birlik, Merih, Kvien, Tore, Eklund, Kari Kalervo, Barcelos, Anabela, Ionescu, Ruxandra, Sanchez-Piedra, Carlos, Tomsic, Matija, Geirsson, Árni Jón, Loft, Anne Gitte, Van Der Horst-Bruinsma, Irene, Jones, Gareth, Iannone, Florenzo, Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete Lund, and Østergaard, Mikkel

Abstract

Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi). Methods Data from 12 European registries, prospectively collected in routine care, were pooled. TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease (<1.3), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <40 mm and Assessment of SpondyloArthritis International Society responses (ASAS 20/40) were assessed at 6, 12 and 24 months. Results A first TNFi was initiated in 24 195 axSpA patients. Heterogeneity of baseline characteristics between registries was observed. Twelve-month retention was 80% (95% CI 79% to 80%), ranging from 71% to 94% across registries. At 6 months, ASDAS Inactive disease/BASDAI<40 rates were 33%/72% (LUNDEX-adjusted: 27%/59%), ASAS 20/40 response rates 64%/49% (LUNDEX-adjusted 52%/40%). In patients initiating first TNFi after 2009, 6097 patients was registered to fulfil ASAS criteria for axSpA, 2935 was registered to fulfil modified New York Criteria for Ankylosing Spondylitis and 1178 patients was registered as having non-radiographic axSpA. In nr-axSpA patients, we observed lower 12-month retention rates (73% (70%-76%)) and lower 6-month LUNDEX adjusted response rates (ASDAS Inactive disease/BASDAI40 20%/50%, ASAS 20/40 45%/33%). For patients initiating first TNFi after 2014, 12-month retention rate, but not 6-month response rate, was numerically higher compared with patients initiating TNFi in 2009-2014. Conclusion A large European database of patients with axSpA initiating a first TNFi treatment in routine care, demonstrated that 27% of patients achieved ASDAS inactive disease after 6 months, while 59% achieved BASDAI <40. Four of five patients continued treatment after 1 year.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results